Construction of a novel signature based on immune-related lncRNA to identify high and low risk pancreatic adenocarcinoma patients

Table 1 The risk scores of each patient in TCGA-PAAD cohort

id	coef	HR	HR.95 L	HR.95 H	P value
AC019117.2\|COLCA1	1.00018	2.71876	1.21165	6.10053	0.01529
AC124789.1\|FOXD2-AS1	0.51762	1.67803	0.96531	2.91697	0.06653
AF001548.5\|CTC-246B18.10	0.48574	1.62538	0.82916	3.18618	0.15723
CH17-360D5.2\|FEZF1-AS1	0.59826	1.81895	0.96362	3.43347	0.06494
CH17-360D5.2\|C14orf132	0.44767	1.56467	0.92152	2.65668	0.09744
CH17-360D5.3\|RP11-23P13.6	1.05298	2.86618	1.47313	5.57655	0.00193
CTA-384D8.35\|PCED1B-AS1	0.81869	2.26752	1.38210	3.72016	0.00119
CTA-384D8.36\|LINC01137	(0.47104)	0.62435	0.33410	1.16676	0.13981
CTC-444N24.11\|RP11-211G23.2	(0.48080)	0.61829	0.35745	1.06947	0.08548
DLGAP1-AS2\|LINC00941	(0.83825)	0.43247	0.24829	0.75328	0.00307
ITGB2-AS1\|WFDC21P	(0.55109)	0.57632	0.31604	1.05096	0.07221
LINC00982\|USP30-AS1	(0.81771)	0.44144	0.24728	0.78806	0.00568
LINC01272\|RP11-554I8.2	(0.59590)	0.55106	0.32958	0.92139	0.02308
NKILA\|UCA1	(0.49934)	0.60693	0.36993	0.99577	0.04807
PP7080\|UNC5B-AS1	(0.56679)	0.56734	0.30669	1.04954	0.07093
RP11-268J15.5\|RP11-326C3.2	(1.65764)	0.19059	0.09902	0.36684	0.00000
RP11-38M8.1\|LINC01559	(0.86880)	0.41945	0.16285	1.08042	0.07190
RP11-631N16.4\|SLC22A18AS	(0.56220)	0.56995	0.32388	1.00299	0.05122
SERTAD4-AS1\|SH3PXD2A-AS1	(0.70243)	0.49538	0.29022	0.84557	0.01003
PVT1\|HOXA-AS2	1.62170	5.06171	2.90274	8.82645	0.00000

ISSN: 1471-230X